Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):2906-2911.
doi: 10.21037/tlcr-2025-461. Epub 2025 Aug 14.

Positioning amivantamab and lazertinib in the therapeutic sequence for EGFR-mutant NSCLC: insights from CHRYSALIS-2 cohort A

Faith Abodunrin  1 , Dillon E Berlin  1 , Christine M Bestvina  1
Affiliations
Editorial

Positioning amivantamab and lazertinib in the therapeutic sequence for EGFR-mutant NSCLC: insights from CHRYSALIS-2 cohort A

Faith Abodunrin et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor (EGFR); advanced non-small cell lung cancer (advanced NSCLC); amivantamab; lazertinib; osimertinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-461/coif). C.M.B. reports personal consulting/advisory boards from AbbVie, Amgen, AstraZeneca, BMS, Daiichi, EMD Serono, Genentech, Gilead, Guardant, Johnson and Johnson, Mirati, Pfizer, Tempus, and Turning Point Therapeutics. She also reports research funding to the institution from AstraZeneca and BMS. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023;389:1935-48. 10.1056/NEJMoa2306434 - DOI - PubMed
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Yang JCH, Kim YJ, Lee SH, et al. 4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. J Thorac Oncol 2025;20:S6-8.
    1. Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med 2024;391:1486-98. 10.1056/NEJMoa2403614 - DOI - PubMed
    1. Cho BC, Kim DW, Spira AI, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med 2023;29:2577-85. 10.1038/s41591-023-02554-7 - DOI - PMC - PubMed